A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate-to-Severe Refractory Autoimmune Diseases

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Moderate to Severe Refractory Autoimmune Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Shanghai Changzheng Hospital, Shanghai, Shanghai Municipality, China

    Contact: Study coordinator (Huji Xu) · xuhuji@smmu.edu.cn · +8613671609764
    Contact: Principal Investigator (Huji Xu)